You are here

pacritinib

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

Endpoints

Tue, 03/1/22 - 10:35 am

Bristol Myers Squibb

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

Endpoints

Tue, 10/25/16 - 09:54 am

FDA puts full clinical hold on CTI BioPharma's blood cancer drug

Yahoo/Reuters

Wed, 02/10/16 - 03:21 pm

Baxalta drops, CTI nosedives after patient deaths & adverse events prompt FDA partial hold

BioPharma Dive

Mon, 02/8/16 - 10:24 am

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St

Mon, 06/1/15 - 10:06 am

mirevtuximab soravtansine

Vascular Biogenics

sacituzumab govitecan

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

TheStreet.com

Sat, 05/30/15 - 05:44 pm

Baxter and its controversial partner CTI claim a win in PhIII blood cancer study

Fierce Biotech

Mon, 03/9/15 - 08:47 am

CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers

Yahoo/PR Newswire

Sun, 12/7/14 - 09:48 am

hematologic cancers

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

Yahoo

Thu, 08/7/14 - 09:00 am

Baxter, Cell Therapeutics announce collaboration to develop pacritinib

Yahoo/Fly on the Wall

Fri, 11/15/13 - 08:43 am

Baxter International

Cell Therapeutics

JAK2/FLT3 inhibitors

Are These 2 High-Flying Biotech Stocks a Buy?

Motley Fool

Tue, 10/8/13 - 08:39 am

Cell Therapeutics

INSYS Therapeutics

Cell Therapeutics' JAK2 Inhibitor Acquisition Is A Smart Pick-Up

Seeking Alpha

Tue, 05/29/12 - 05:09 pm

Cell Therapeutics